Please complete all fields below.
now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve
Latest news Commentary: Dermatologists and SARS - CoV - 2: the impact of the pandemic on daily practiceJuly 22, 2020Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage. Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque PsoriasisJuly 20, 2020Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis. Pathogenesis of PsoriasisJuly 14, 2020Dr. Stingl discusses differences in the pathogenesis of plaque psoriasis and pustular psoriasis. Spoiler alert: it's the neutrophils. PsoProtectMe now available in multiple languagesJuly 09, 2020PsoProtectMe now available in multiple languages More News